Molly Grammel is a partner in Goodwin’s Intellectual Property Litigation practice and is a member of the firm’s Life Sciences Disputes group. She has extensive federal trial experience and has worked on IP cases involving software, hardware/high tech and pharmaceuticals.

Ms. Grammel has experience litigating in federal and state trial and appellate courts as well as in proceedings before the United States Patent and Trademark Office. She has worked on cases relating to a variety of different technologies.





At Goodwin, Ms. Grammel has been an active member of teams litigating three federal jury trials, one federal bench trial, and one federal preliminary injunction hearing. She has also worked on appellate matters in the Federal Circuit, the First Circuit, and the Supreme Judicial Court of Massachusetts, as well as inter partes review proceedings.

Representative matters include:

  • Certain Pre-Filled Syringes for Intravitreal Injection and Components Thereof, 337-TA-1207. Representing global healthcare company in ITC investigation and related litigations and inter partes review proceedings.
  • Manufacturing Resources Int’l, Inc. v. Civiq Smartscapes, LLC et al., C.A. No. 17-269-RGA (D. Del.). Representing defendants against pending claims of patent infringement, trademark infringement, and unfair competition and deceptive trade practices claims relating to digital outdoor displays. Successfully obtained dismissal with prejudice of 13 asserted patents as well as all trademark infringement claims. Asserted patents include digital display system and cooling method claims.
  • Genentech, Inc. et al. v. Celltrion, Inc. et al., C.A. Nos. 18-95-CFC, 18-1025-CFC (D. Del.). Represented Celltrion and Teva in BPCIA dispute regarding proposed biosimilar to HERCEPTIN® involving 40 patents, including during the pre-suit patent dance and during ensuing litigation. Asserted patents included antibody manufacturing process, method of treatment and diagnostic method claims.
  • Reckitt Benckiser Pharmaceuticals Inc. et al. v. Dr. Reddy’s Laboratories, S.A. et al., C.A. Nos. 17-7111-KM, 18-1775-KM, 18-5288-KM (D.N.J.). Representing Dr. Reddy’s in second-wave infringement suit regarding Dr. Reddy’s proposed generic versions of SUBOXONE® (buprenorphine/naloxone) sublingual films, including during preliminary injunction proceedings and successful expedited appeal therefrom, resulting in a finding by the Federal Circuit that the district court committed legal error and abused its discretion in entering an injunction, and that one of the plaintiffs’ second-wave infringement cases is likely barred by claim preclusion.
  • Reckitt Benckiser Pharmaceuticals Inc. et al. v. Dr. Reddy’s Laboratories, S.A. et al., No. 14-1451-RGA (D. Del.). Represented Dr. Reddy’s in Hatch-Waxman suit regarding Dr. Reddy’s proposed generic versions of SUBOXONE® (buprenorphine/naloxone) sublingual films, resulting in trial judgment of non-infringement of all asserted claims, which was affirmed by the Federal Circuit on appeal. Directed a witness at trial and had substantial involvement in development and presentation of noninfringement defenses before and at trial. Asserted patents included pharmaceutical thin film formulation and manufacturing process claims.
  • Veracode, Inc. et al v. Appthority, Inc., No. 12-10487-DPW (D. Mass.). Represented patent owner in infringement suit against a competitor asserting patents relating to analysis and review of source code, resulting in jury verdict and post-trial judgment as a matter of law of willful infringement and entry of a permanent injunction.
  • Various non-public representations, including counseling biosimilar developer in pre-litigation matters and confidential arbitration proceedings involving pharmaceutical IP licensing disputes.

In addition to her IP work, Ms. Grammel was also one of the Goodwin attorneys on the federal trial team that defended former SAC Capital Advisors portfolio manager Mathew Martoma. In the largest-ever insider trading prosecution brought to trial, Mr. Martoma faced charges that he improperly obtained non-public information about the results of a high-profile pharmaceutical clinical trial and used this information to make trades resulting in profit and avoided losses of over $275 million.

Pro Bono

Ms. Grammel devotes a significant portion of her practice to pro bono projects. While at Goodwin, she has represented indigent clients in various matters including an appeal of eviction proceedings, pursuit of civil rights claims under 42 U.S.C. § 1983, and defense of criminal securities fraud allegations. Ms. Grammel has also assisted legal permanent residents in applying for U.S. citizenship and is currently representing four young girls in their petition for Special Immigrant Juvenile status, as well as two Ugandan refugees seeking asylum in the United States following persecution in their home country on the basis of their sexual orientation.

In addition to these projects, in 2017, Ms. Grammel completed a six-month rotation with the Middlesex County District Attorney’s Office. During this time, she first-chaired fifteen trials, including five jury trials. Ms. Grammel also argued dozens of evidentiary and non-evidentiary motions, including successfully arguing for the admissibility of presumptively excluded evidence at a consolidated hearing addressing a group of cases brought in Woburn District Court prior to 2014.

Professional Activities

Ms. Grammel is a member of the Boston Bar Association, the American Bar Association and the National Association of Women Lawyers.


Ms. Grammel has been recognized by The Best Lawyers in America Ones to Watch for her work in Litigation - Intellectual Property and Litigation - Patent 2022. 

Ms. Grammel was recognized in Best Lawyers: Ones to Watch 2021 for her work in Litigation – Patent.

Ms. Grammel was a recipient of the Levy Scholarship, the University of Pennsylvania Law School’s largest merit award. She served as an Articles Editor for the University of Pennsylvania Journal of Constitutional Law, and was Vice President of the University of Pennsylvania chapter of Lambda Law. Ms. Grammel was also selected as a member of the Penn Law National Trial Competition team in 2013.

In The News









J.D., 2013
University of Pennsylvania Law School
(magna cum laude)
B.A., 2010
University of California, Los Angeles
(magna cum laude, Phi Beta Kappa)





U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the District of Massachusetts
U.S. Court of Appeals for the First Circuit
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.